Dr. Sager is a cardiac electrophysiologist who has had a long career in academia, drug development and regulatory policy. He was a tenured faculty member at the UCLA School of Medicine and is an Adjunct Professor of Medicine at the Stanford University School of Medicine. Senior pharmaceutical industry leadership roles include Vice President, CV/Metabolic Development at Gilead Sciences and Executive Director at AstraZeneca, with major development leadership on multiple drugs (e.g., Zetia, Vytorin, Crestor, Letairis and Brilinta), NDA’s and sNDA’s, and was a BOD member of Anthera, Inc, a public biotechnology company. He is a co-founder of LQT Therapeutics (now Thryv Therapeutics).

He is a past chair of the FDA Cardiovascular and Renal Drugs Advisory Committee and a Founding Member and Executive Committee member of the FDA-Sponsored Cardiac Safety Research Consortium. He has played a major international leadership role in CV safety issues in drug development, public health policies regarding drug safety, and was the ICH E14 (“the QT Guidance”) PhARMA Expert Working Group Topic Leader. He holds an M.D. from Yale University School of Medicine, B.S. degrees in biology and chemistry from the Massachusetts Institute of Technology, trained in internal medicine, cardiology, and cardiac electrophysiology at the Yale School of Medicine, and has published more than 200 original manuscripts and abstracts.

• 

  Chief Medical Officer in Thryv Therapeutics

  We will relentlessly pursue precision treatments targeting SGK1 to enable people to live their absolute best lives.Without Limits.